Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) had its price target boosted by Wells Fargo & Company from $48.00 to $72.00 in a research note issued on Wednesday,Benzinga reports. According to MarketBeat, Celldex Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $54.62. Get Celldex Therapeutics alerts:Check Out Our Latest Stock Analysis on CLDXCelldex Therapeutics Price PerformanceCelldex Therapeutics stock traded up $0.27 during trading hours on Wednesday, hitting $35.84. Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last announced its earnings results on Thursday, May 7th. Recommended StoriesReceive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.